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Abstract
This is a narrative review considering the use of e-cigarettes and heat-not-burn tobacco products. Advantages and disadvantages 
of both devices, including biological and clinical consequences, were described. The role of these products in limiting tobacco 
dependence was also discussed. Possible implications for clinical practice were addressed as well.
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Introduction
Many smokers want to quit, but a long-term 
success achieve only few. All tobacco products 
are addictive. Health consequences of nicotine 
dependency are serious. Apart from nicotine, 
a variable exposure to many toxins and carci-
nogens is associated with the use of primary 
addictive products. Manufacturers try to modify 
tobacco articles using products with filtres, „low 
tar“ and „light“. However, all these attempts 
have not resulted in less harm. Newer proposals 
of nicotine use may be divided into two types: 
e-cigarettes and heat-not-burn products (HNB). It 
is being considered, if these items are able to end 
or at least markedly limit a liking for smoking . 
Heat-not-burn (HNB) tobacco products
HNB are devices that deliver an aerosol from 
heated not combusted cigarettes. Three compa-
nies produce different systems based on tobacco 
heating (IQOS-Philip Morris, Glo-British Ame-
rican Tobacco) or non-tobacco substrate (IFuse 
Japan Tobacco) [1]. All systems contain a charger, 
an electronically controlled heating element and 
a holder (Fig. 1).
Reports from Europe and Asia point that 
a number of HNB users is rapidly increasing, 
exceeding in 2017 in Japan 50% of the adult po-
pulation [2, 3].
Troublesome data collections
Epidemiological data about results of classi-
cal tobacco smoking are well known. Difficulties 
arise with regard to studies on e-cigarettes and 
HNB. Variable populations and various motiva-
tions to use, different law limitations in particu-
lar countries, many demographic discrepancies 
and relatively short time of the presence of pro-
ducts on markets create difficulties in comparing 
the results of epidemiological data collections. 
In a case of e-cigarettes, many complications are 
caused by a lack of standardized and controlled 
production systems. The number of liquids 
used by e-cigarettes manufacturers exceeds 8 
thousand, and the number of devices amounts 
to about 1,000 [4]. Liquid products from the 
same producer contain not replicable percent of 
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Figure 1. The construction of HNB devices
agents. Thus, some liquids differ signifficantly 
from the others [5]. 
A  relatively small number of independent 
studies on HNB exists. To the beginning of 2018 
one could have found only eleven independent 
studies based on EBM methodology, mostly 
performed in laboratories [1]. Only 4 of them 
have been epidemiological and their results are 
undoubtedly insufficient to conclude about the 
usefulness of HNB for conventional cigarette 
smoking limitation. 
Biomarkers
Good biomarkers are characterized by undo-
ubted dose-response relationship with exposure to 
chemical agent, quantitative and qualitative identi-
fication over low and high concentrations, detection 
in biospecimens of blood, urine or saliva, stability 
in specimens during storage for future analyses [6].
Hundreds or even thousands of chemicals 
with potential harm to human health have been 
identified in both e-cigarettes and HNB. However, 
we cannot be satisfied with monitoring of health 
effects and their expected positive influence on 
tobacco dependence. The lack of validated bio-
markers seems to be one of the most important 
public health problems. Commonly used tests 
for nicotine exposure as TSNA (tobacco-specific 
nitrosoamine metabolites) point only exposure 
to e-cigarettes, HNB or nicotine replacement 
therapy, but biomarkers of real health effects in 
humans that could be used in practice are not 
available. Only few research groups have per-
formed not expensive, sufficiently specific and 
sensitive assays to differentiate tobacco use from 
other nicotine-containing products. 
Biomarkers of harmful or potentially harmful 
compounds in people exposed to HNB remain at 
much lower level than in smokers [6]. 
Category of emissions
Usually, emissions from tobacco, HNB or 
e-cigarettes are categorized according to a place 
of stream as mainstream, sidestream or secon-
dhand [7]. Mainstream is commonly used as the 
most important category. It takes a central part of 
smoke that a man draws on. Mainstream is often 
described in many laboratory studies by the use 
of standardized machines, because it replicates 
human smoking. Sidestream measurements are 
studied in standardized laboratories to measure 
environmental exposure. Secondhand smoke 
combines both exhaled mainstream and sidestre-
am exposure.
Mainstream emission
The standards of studied emissions produced 
by machines distinguish between methods re-
commended by IOS (International Organisation 
for Standardization) and Health Canada Intense 
(HCI). However, many problems arise, when the 
results of studies in real life and standardized 
exposure are compared. Reference cigarettes 
differed between researches performed in dif-
ferent regions. Some methodological problems 
of measurements of aerosol constituents are 
stated, but undoubtedly, HNB produces less 
harmful emission [8]. Another problem is 
a difference between cigarettes manufactured 
as a reference for studies and commercially ava-
ilable products. 
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It is reasonable to accept that a level of ma-
instream decides on an influence on dependence 
on the product. Nicotine emission in mainstream 
ranges between 1.1 and 1.41 mg in IQOS and is 
about 50% lower in GLO [8]. In comparison with 
conventional cigarettes, a mainstream in IQOS 
contains 57 to 83% of nicotine according to inde-
pendent study [9]. There is no independent inve-
stigation on a level of nicotine in GLO or iFuse. 
Many papers have compared the levels of 
HPHC (Harmful and Potentially Harmful Con-
stituents) like polycyclic aromatic carbons, tar, 
carbon oxide, nitrosoamines, and nicotine- deri-
ved agents. When machine regimens have been 
used, it seems that mainstream contained lower 
levels of carbon oxide (reduction almost by 99%), 
tar, and other HPHC than cigarettes [8, 10]. Su-
prisingly, one independent study has reported 
more nitrosoamines and other nicotine-derived 
amines [11]. 
Sidestream and secondhand emission
One research funded by a tobacco company 
that does not manufacture HNB products, has 
suggested that HNB produces a higher number of 
particulate matter than e-cigarettes [12]. However, 
six other authors , including three independent 
studies have reported that e-cigarettes and HNB 
emission of particulates from e-cigarettes and 
HNB is almost equal to the level of 25% of cigaret-
te smoke [13–18]. As a matter of fact, e-cigarettes 
produce more particulates, but dispersing of them 
in sidestream from ICOs lasts longer. However, 
a diameter of most particles produced by IQOS 
is just below 1000 nm, which is regarded as re-
latively safer than lower mass particles [13]. The 
number of respirable fraction of particles is higher 
in GLO and cigarette smoke, however, a global 
mass of particles in GLO was lower [18].
HPHC in secondhand emission were repor-
ted [17, 18]. The methods of assessment differ 
between independent and company funded stu-
dies. This may be an explanation why particulate 
matter and acrolein in an independent research 
were detected [14], when in company funded 
did not [17].
Animal and human studies
Plasma nicotine concentration in people 
exposed to e-cigarettes and HNB exceeds half 
of the levels in people exposed to cigarettes. 
However, expired carbon oxide in e-cigarettes or 
HNB users constitutes about 25% of a number 
of parts per milion (ppm) observed in smokers 
[19]. According to nicotine consumers, smo-
king gets more satisfaction than an alternative 
delivery, but smokers do not perceive less 
satisfacion as unbearable. HNB users reported 
lower satisfaction than smokers, but a use of 
HNB suppressed significantly the need for 
smoking [19]. 
In people who switched from smoking to 
ICOS use, there were observed a large reduction of 
biomarkers concentrations and expression of sys-
temic imflammation, oxidative stress, endothelial 
dysfunction and a decrease of serum high-density 
lipoprotein [20–23]. Positive changes of lung lipid 
profile were also stated [24]. RCT studies confirm 
expectations that switching from smoking to HNB 
reduces but does not completely remove exposure 
to HPHC. Such trials lasted not longer than 90 
days and one cannot conclude about a  longer 
influence of switching from smoking dependence 
to HNB on health effects [25].
In vitro RNA toxicogenomics assessment 
showed reduced biological effect of HNB when 
compared to cigarette [26]. MicroRNA expres-
sion indicates that HNB aerosol evokes reduced 
effects on the lung tissue compared to cigarette 
smoke [27, 28]. 
The question if HNB products may be useful 
in the removal of nicotine dependence remains 
open. No independent study is available. Daily 
use of HNB in people who switched from smo-
king remains on the level of a use of conven-
tional cigarettes. Observational studies have 
showed different results, but conclusions do not 
allow to regard HNB as a much useful proposal 
[22, 29, 30]. In an interesting case report from 
Japan, a man in whom eosinophilic pneumonia 
developed following a rapid increase of daily HNB 
use, has been described. 
Are HNB products useful in limiting tobacco 
dependence?
The question has been discussed lately in the 
US and UK [32, 33]. The most important conc-
lusions from the British Report are the following:
1. Heat- not- burn products still pose a risk to 
users. There is likely to be a reduction in risk 
for cigarette smokers who switch to heat- not- 
burn products but quitting entirely would be 
more beneficial.
2. People using these products are exposed to 
between 50 and 90 percent less harmful and 
potentially harmful compounds, compared 
with conventional cigarettes.
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3. There is a  reduction in risk to bystanders 
where conventional smokers switch to heat- 
not- burn products. 
The FDA has asked if scientific studies have 
shown that switching from cigarettes to the ICOS 
system can reduce the risk of tobacco-related 
diseases. The answer is negative.
Thus, no official statements are convincing 
with regard to any limitation of nicotine de-
pendence due to the use of HNB products. The 
most important reason for the cautious opinion 
is a  lack of independent long-term studies into 
expected effects of HNB products resulting in 
nicotine dependence limitation. The likelihood 
that never smokers, particularly youths, will be-
come established HNB users is low. According 
to the FDA, the probability that former smokers 
will re-initiate tobacco use with HNB seems to be 
also low. The chance that smokers will become 
long-term dual users is usually assessed as high 
or moderate. This is important in the light of the 
discussed problem of the possibility of complete 
switching from conventional smoking to the use 
of HNB products. Published data have given no 
answer to this question. 
Fundamental question for pneumologists
To the end of 2018 no data about an influence 
of switching from conventional cigarettes to HNB 
use in people suffering from chronic airway dise-
ase have been published. Human studies are very 
poor and avoid the answer to many problems con-
cerning advantages and disadvantages of such swi-
tching. Very little is known about the persistence 
of liking for HNB use instead of cigarettes. Neither 
the FDA/ British Government nor clinicians are 
able to compare effects of switching to e-cigarretes 
and HNB. However, suggestions that HNB are only 
signs of novel tobacco industry strategy to slow 
progress in tobacco control seems to be exaggera-
ted [34]. Undoubtedly, burned, not combustible 
cigarettes contain less harmful and potentially 
harmful products than conventional cigarettes. In 
opposite to e-cigarettes consumption, a number 
of people starting their nicotine dependence with 
HNB is extremally low. The use of HNB does not 
seem to be convenient in comparison with smo-
king. Thus, one cannot see an important danger 
for a wide use of HNB in the general population. 
E-cigarettes
Approximately 15 % of adult people in the 
USA use e-cigarettes occasionally. The number of 
current e-cigarettes consumers exceeds 7% , and 
systematically increases [35]. In many countries, 
the highest rates are reported in adolescents and 
people below 25 of age [36]. The prevalence of 
tobacco smoking has fallen lately, but in some 
countries, users of e-cigarretes exceeded the 
number of smokers [37]. Among students of Polish 
non-medical universities, 37% declared as ever 
using e-cigarettes. This proportion was a  little 
lower in health educated medical students but 
still exceeded 25% [38]. E-cigarettes both in Po-
land and in the US are utilized mostly by people 
parallelly smoking conventional cigarettes (dual 
users) [39–41]. A typical e-cigarette consumer is 
a male, poorer, nonmarried, white, young [42]. 
Devices and liquids
Each e-cigarette consists of an atomizer with 
a battery heating a metal coil, a reservoir of liquid, 
a cartridge and a silica wick (Fig. 2). 
Electronic cigarettes encompass a variety of 
products looking like a classical cigarette (first 
generation, „cigarlikes“) or larger devices to hold 
the liquid. The most popular in the USA system 
named JUUl seems to be more convenient and 
probably safer because it is not liable to accidental 
outburst of a device [43].
The types of cigarettes differ significantly in 
voltage and resistance of a coil. A variety of metals 
are used but all contain nickel. 
There are a lot of liquids that may be vaped 
and sucked by the user. In fact all liquids contain 
nicotine in a variety of concentrations and many 
flavoring artificial additives [44] (Table 1).
The most important differences between first 
and third generation devices consist in better 
control over a liquid stabilisation and the physi-
cal features of vaporized aerosol. The power in 
electrical circuit of coils varies with the age and 
temperature of metal components [45]. Increased 
power results in the production of volatile car-
bonyl compounds, including carbonyl nickel re-
garded as a very strong carcinogen. Additionally, 
other metals like chromium, copper, zinc, silver 
and heavy metals have been found in vaporized 
liquids [44]. Metal coils of the majority of devices 
comprise nickel/chromium or kanthal (chromium/
aluminium/iron). Even short exposure to metal 
fumes influences lung immunological system le-
ading to metal fume fever, asthma and cancer [46]. 
Heating is also responsible for the aldehyde 
contamination of aerosol, because both glyceri-
ne and propylene glycol form aldehydes while 
heating [47]. E-cigarette liquid may be contami-
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Figure 2. The construction of E-cigarette
Table 1.  The most frequent constituents of liquid  






















Nitroso and  
methylnitrosoamines
Toluene
Nickel and nickel carbonylate
Chromium, lead, copper,  
cadmium, tin
Silica
nated with ethylene glycol as a  result of inap-
propiate manufacturing. Ethylene glycol has not 
been approved in any products for humans [48]. 
A temperature of aerosol is very often out of control 
and cases of airway scalding were described [49]. 
The highest power the biggest production of par-
ticulates, thus the resistance of coil plays a vital 
role in toxicity. The resistance of coil influences 
the manufacturing of different contents of aero-
sol. Moreover, the higher power and resistance 
the more particles are deposited in the alveolar 
space [44].
 The lithium battery is responsible for explo-
sions both while charging and aerosol heating 
[50]. Many accidents with the mouth and eye 
injuries were reported. Explosions and their 
consequences are so common that a special clas-
sification has been proposed [51].
Liquid pH plays a role in the toxicity of aero-
sol [52, 53]. Apart from nicotine, which is affected 
by pH , some liquids contain nicotyrine that inhi-
bits nicotine metabolism and increases nicotine 
toxicity [54, 55]. All ingredients in e-cigarettes 
contain nicotine, propylene glycol or vegetable 
glycerine and flavors. Nicotine concentrations in 
liquids range from 15 to 25 mg/ml but in some 
cases exceed 25 mg/ml. The nicotine contents in 
liquids is not repeatable and evidence of quality 
assurance is usually absent. A conventional ciga-
rette delivers only about 2 mg of nicotine, which 
is one thirty of nicotine LD50 value [56]. Thus, 
an ingestion of the liquid can be fatal, especially 
for children [57]. The total calls for house single 
unintended exposures in the US exceed 1 milion 
per year [ 58]. 
JUUL device uses protonated nicotine for-
mulations derived from loose-leaf tobacco. It 
contains up to 10 times more nicotine than other 
e-cigarettes [43]. Consciousness of nicotine de-
pendence among people is very low. Two thirds 
of young Americans do not know that nicotine is 
present in all JUUL products [43]. 
Apart from variable nicotine contents, also 
other components have been found by many 
investigators as differering from what was indi-
cated on a label. No manufacturer inform about 
the presence of metals, arsenic and other toxic 
agents in liquids. 
Although glycerine and propylene glycol 
have been regarded by the FDA as safe, they 
form toxic agents while heated [59]. Aldehydes 
produced in a heating process are responsible 
Advances in Respiratory Medicine 2019, vol. 87, no. 2, pages 123–134 
128 www.journals.viamedica.pl
for airway irritation, symptoms and a decrease 
of FEV1. Cinnamaldehyde has been shown as 
a mutagenic agent [60, 61]. Moreover, aldehydes 
are also very strong carcinogens. They are detec-
ted in a variety of e-liquids in concentrations of 
10–40 mg/ml — enough to be of toxic relevance 
when inhaling [62]. 
Flavoring components, especially cinnamon 
and diacetyl (a buttery flavoring) preferred by 
many adolescents, produce airway discomfort. In 
the past, such flavoring agents were reported as 
a cause of bronchiolitis obliterans [63]. 
Also, a puffing behavior influences the toxi-
city of e-cigarettes. Flow rate probably does not 
impact the nicotine absorption but a  time of 
puffing do, because a coil is heated for a longer 
time [64]. The e-cigarrete puff duration is longer 
than a puff during smoking [65].
Indoor air quality
Both e-cigarettes and HNB diminish indoor 
air quality. Safety of non-users in the field of 
general health or nicotine dependence is unac-
ceptable and more hazardous than nicotine 
replacement products. E-cigarette vapors influ-
ence particulates PM2.5  and ultrafine particles 
(UFP) concentrations/counts at close proximity 
distances indoors. The levels of PM2.5 increased 
160-fold at a distance of 0.5 m, and 103-fold at 
1 m. The corresponding growths in UFP counts 
were 5.2, and 3.0-fold higher, respectively [66]. 
However, chemical quality of indoor air according 
to the presence of benzene, toluene or aldehydes 
is much better than in homes of smokers [67].
Direct and indirect influence on airway  
and alveolar epithelium
An in vitro study on airway and alveolar 
epithelium deliver undoubted evidence that cel-
ls exposed to e-cigarettes are strongly affected. 
A cellular metabolism of amino acids decreases, 
a cell viability is reduced, but a production of 
inflammatory cytokines, especially IL-8 and IL-6, 
and also reactive oxygen species increase as a re-
sult of exposure to both the entire liquid and flavo-
ring compounds [68–70]. Oxidative stress develops 
following direct action of toxic compounds on the 
airways and alveolar epithelial cells [71]. Moreo-
ver, e-liquid decreases antioxidant activity [72]. 
Neutrophils and macrophages are probably the 
largest source of reactive oxygen species.
Many tested compounds cause a destruction 
of epithelial barrier, especially when an exposure 
lasts longer. One interesting experiment described 
an influence of e-cigarettes on epithelial antivirus 
defense. Exposed cells produced a decreased amo-
unt of antiviral proteins, and the load of viruses 
inside cells was highly increased [73].
In vitro models of e-cigarette exposure of 
alveolar epithelium should be treated very cau-
tiously. Investigators have used the cell line 
of human adenocarcinoma that unlike natural 
alveolar epithelium, do not form a tight junctions 
in culture [74]. In adenocarcinoma cells, a do-
se-dependent increase of lactate dehydrogenase 
according to necrotic cell death was observed. 
Moreover, antimicrobial defense was affected by 
an exaggerated growth of methicillin-resistant 
Staphylococcus bacteria and diminished effecti-
veness of endogenous antibacterial peptides [75]. 
It is important that e-cigarette exposure on 
adenocarconoma cells cause cell death and decre-
ase cell viability [71]. It is well established that 
these cells are highly resistant to death affecting 
agents. Thus, one can judge that e-liquids might 
be extremely toxic. 
Not only epithelium, but also endothelial 
cells are strongly affected following e-cigarette 
exposure in a dose-dependent manner [76]. 
Animals exposure
The lungs in animals exposed during experi-
ments to e-cigarettes are directly strongly affected. 
In mice exposed to aerosol from e-cigarettes 
for 5 hours in each of 3 days, an increase of the 
concentration of several cytokines in broncho-
alveolar lavage was observed [77]. Mice develo-
ped oxidative stress with a significant reduction 
of glutathione. Another group of investigators 
confirmed oxidative stress with a different para-
meter [78]. 
Interesting data were showed by authors 
dealing with experimental models of lung emphy-
sema. Mice exposed to a nebulization machine 
developed histological pictures of emphysema, 
an increased mucin production, airway resistance 
and airway inflammation [79]. 
Also, in mice exposed separately to aerosol 
inspired by nose, BAL content of inflammatory cy-
tokine associated with emphysema or interstitial 
lung diseases was recorded [71, 75]. 
Undoubtedly, mice exposed to e-cigarettes 
are more succeptible to infections. Destroyed de-
fense mechanisms leading to increased bacterial 
colonization including Streptococcus pneumo-
niae and MRSA strains in the airways seem to 
be especially harmful. Both innate and adoptive 
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defense mechanisms, local and systemic, are 
affected [75, 80]. 
Murine exposure just after a birth impairs 
their development [81]. This observation cor-
responds with many evidences of an influence 
of nicotine-induced neonatal impairment in 
humans. Although no human data on pregnant 
women are available, these suggestions force to 
act with due caution as far as recommendations 
for alternative method of smoking in pregnancy 
are concerned [82].
Lung toxicity in humans
There is no data from studies lasting longer 
than one year on effects of exposure to e-ciga-
rettes or HNB. A cross-sectional study including 
45 thousand of adolescents reported coughing 
and sputum production, both in former or dual 
smokers and never smokers [83]. In comparison 
to never smokers, current e-cigarettes users deve-
loped more asthma symptoms, wheezing and full 
bronchitic symptoms [84]. A short exposure ad 
libitum in former smokers produced an increase 
of airway resistance and a decrease of exhaled 
nitric oxide, which suggests a growth of oxidative 
stress [85]). 
Considering particular agents of e-liquid, we 
cannot cleary point to one component responsible 
for deleterious effect in the lungs. A recent study 
with the use of both murine and human epithelial 
cells exposed to nicotine alone, nicotine-conta-
ining and nicotine-free condensate has revealed 
that even nicotine alone causes disruption of 
lung epithelial barrier, lung inflammation and 
diminished cell proliferation. A pro-inflamma-
tory effects of e-cigarette vapor condensate also 
depend on induction of apoptosis and necrosis 
of human alveolar macrophages [86]. Disrupted 
function of these cells leads to succeptibility to 
infection and probably cancerogenesis as well. An 
experiment with wholly nebulized nicotine, acro-
lein, propylene glycol and glycerol has produced 
lung inflammation. The effect of acute exposure to 
these aerolized agents lasts shorter than changes 
induced by combustible tobacco smoke. Moreo-
ver, lung inflammation develops due to defective 
local and systemic immunological reactions to 
bacteria and viruses in exposure to e-cigarettes. 
Cardiovascular effects of e-cigarettes
E-cigarettes use and smoking have been re-
sponsible for many cardiovascular changes. Both 
have resulted in defects of heart development and 
malformation and cardiac dysfunction following 
a decrease of expression of cardiac transcription 
factors [76]. 
Similarly to smoke, e-cigarettes have elevated 
nicotine-depending blood presure and heart rate 
in acute observational or experimental studies 
[87]. Some authors have postulated activation of 
sympathetic central outflow as a part of „spleno-
cardiac axis“ [72]. However, the influence of these 
cardiac parameters is weaker than acute smoke 
exposure [87]. In one study, cigarette smoke in-
creased arterial stiffeness but e-cigarette did not 
[88]. Thus, acute effect of a e-cigarette use seems 
to be less harmful than cigarette smoking, but 
effects of a long-lasting exposure have never been 
described. In a limited number of epidemiologic 
studies, no risk of myocardial infarction was 
observed [89].
Are e-cigarettes really less toxic?
E-cigarettes are commonly regarded as less 
toxic than smoking. Acute experiments on cell 
cultures in both whole body murine and in hu-
mans have suggested that lung and cardiovascular 
toxicity in e-cigarette exposed subjects is less har-
mful. Cold e-liquid contains less carcinogens and 
cardiovascular toxic agents than cigarette smoke. 
However, heated liquid is a source of potential 
strong carcinogens, including benzene [90–92]. 
The heating of liquid leads to formation of a wide 
range of degradation products, including carci-
nogens. Benzene formation was detected in all 
devices except JUUl [90]. Exposure to this agent 
exceeded 100 mcg/m3 and is not a negligible risk 
factor of carcinogenesis, though is lower than pro-
duced by combustible tobacco cigarettes. Heated 
coils and wicks create metals and silica fumes 
containing toxic and carcinogenic products that 
may be responsible for neoplasms development, 
inflammation and silicosis.
In opposition to commonly accepted view 
about minimal toxicity, some authors observed 
that bone-derived mesenchymal stem cells exhi-
bit overproduction of reactive oxygen species on 
higher level than cells exposed to cigarette smoke 
[93]. Moreover, e-cigarette changes morphology, 
cell-cell communication and mesenchymal cells 
proliferation more strongly than a  traditional 
cigarette. 
E-cigarettes influence nicotine yield and 
increase a plasma nicotine concentration. One 
study suggests that 10 puffs of e-cigarette gives 
higher nicotine plasma concentration than one 
tobacco cigarette [94]. It is well established that 
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a regular use of high doses of an addictive sub-
stance leads to greater dependence. 
In adolescents, nicotine dependence starts 
from the use of e-cigarettes. Most of young people 
become dual users in a short time or even change 
their likings to smoking [95, 96]. Nicotine absti-
nence symptoms are well described and consist 
of anxiety, depression, concentration difficulties, 
decreased heart rate with diminished general 
capacity to exercise, irritability and insomnia, 
weight gain.
Importantly, women of childbearing age 
start to use e-cigarettes, because they are convin-
ced that they do no harm. Nicotine crosses the 
placenta and actively influences neonates deve-
lopment [97]. It is well known that children of 
women smoking during pregnancy or passively 
exposed to smoking are characterized by cognitive 
impairment, anxiety, irritability and some other 
somatic symptoms. Nicotine acts on acetylocho-
line receptors detectable on very early stages of 
neonatal development and are situated not only in 
central nervous system but in a whole body [97]. 
This may explain an increased risk of some future 
disorders such as type II diabetes, hypertension, 
obesity and chronic airway diseases. 
Acute poisoning and accidental events
E-liquid poisoning has been reported many 
times. The routes of poisoning comprise not only 
the mouth but also skin and eyes. Poison centers 
have noted thousands of cases mostly among 
children [98]. Liquid in suicide attempts has been 
used intravenously and orally. 
The FDA have collected reports of cases of 
adverse events probably related to e-cigarettes 
use, including burns of the airways and fa-
ces from device explosions, severe pneumonia, 
liquid pneumonia, eosinophilic pneumonitis, 
heart failure, ulcerative colitis, chronic neutro-
philia, ischemic stroke [99–102]. On the other 
hand, switching from smoking to e-cigarettes 
use improves asthmatic symptoms, hemoglobin 
oxygenation and blood saturation, coughing and 
sputum production. 
Is it time recommendation?
The question to what extent e-cigarettes might 
be useful for quitting smoking remains open. Many 
authors believe that e-cigarettes effectively repla-
ce smoking, especially in COPD patients [103]. 
However, observation time in many studies en-
compassed from 3 to 12 months. Some investiga-
tors have found no effect on long-term cessation 
of smoking [104]. 
National experts point to a lack of results of 
long-term epidemiological studies. Analyses ac-
cording to EBM criteria are troublesome because 
there have been showed only few RCT studies in 
rather small populations. 
On the other hand, the use of e-cigarettes 
and HNB still rise sharply. The consciousness of 
many disadvantages, including dependence is 
very low. Many young people start to use these 
products as never smokers. In a short time they 
become dual or polyusers. 
It is true that final decisions should be delay-
ed, but in many countries national experts groups 
published recommendations based on available 
data. The FDA has delayed a comprehensive plan 
for tobacco and nicotine regulation until 2022. 
In Europe, recommendations described cautious 
suggestions, especially when comparing different 
products. The British Department of Health & 
Social Care pronounces: „heat-not-burn products 
still pose a risk to users... experts were unable to 
precisely quantify the risk from heat-not-burn 
products compared with conventional cigarettes 
because limited data is available“.
Opinions have changed lately from explicitly 
negative to more cautious. Yet, in 2015, e-cigaret-
tes were regarded as a Trojan horse that would 
slow the process of smoking denormalization, 
reducing the number of people trying to quit, 
and seducing young smokers. Changes have been 
observed from „guilty until proven innocent“ to 
„could be beneficial for adult smokers seeking to 
quit“ [105]. 
However, countries differ according to de-
mography, number of smoking people, espe-
cially adolescents and even a smoking manner. 
In Eastern Europe, the custom of offering one 
another cigarettes is very popular. Formulation 
of HNB practically excluded this behavior and 
seems to be a way to limit smoking . The number 
of smoking women and the number of dual or 
polyusers influence non only the effectiveness, 
but also foreseen ways of smoking cessation. Both 
nicotine dependence and withdrawal symptoms 
varied as a function of gender.
E-cigarettes and HNB products are only one 
of many ways to limit smoking. Whilst e-cigaret-
tes and HNB have been characterized as being 
less harmful than combustible tobacco, only 
a minority of current smokers, around 15%, are 
going to use these devices [106]. Smokers princi-
pally explain it in terms of pleasure they derive 
from smoking [106]. In some recent guidance for 
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primary care, neither e-cigarettes nor HNB exists 
[107]. It seems, however, that actual knowledge 
allows physicians to take into account both me-
thods individually recommended and applied in 
smokers. These modern proposals ought to be an 
additional way of smoking cessation in people, in 
whom traditional methods occurred ineffective. 
Switching cannot finish the process of quitting 
smoking, but should be only one of the stages 
of eliminating nicotine dependence. It seems 
that in the Polish population, HNB systems are 
more effective in smoking cessation. According 
to a report of an independent institute of opinion 
polls (CBOS), in the group of 1000 adults using 
e-cigarettes or HNB that have been trying to stop 
smoking, half of HNB users achieved the purpose 
while among e-cigarette users only one quarter 
succeeded [108]. On the other hand, in randomly 
assigned adults in the UK, e-cigarettes occurred 
more effective at smoking cessation than nicotine
-replacement therapy, when both products were 
accompanied by behavioral support [109]. 
However, the most important question that 
might be considered in individuals is a balance 
between expected success of antinicotine treat-
ment and disadvantages from the management. 
Prolonged application of e-cigarettes associated 
with a significant exposure to many harmful sub-
stances, especially non standardized contents of 
flavoring agents is unacceptable. Many opinion 
leaders postulate that national health care deci-
sion-making institutions should simply ban the 
sale of flavored nicotine products for use in e-ci-
garettes [110]. Physicians ought to remember that 
both smoking and alternative methods, including 
e-cigarettes or HNB use are disadvantageous to 
human health. 
Conflict of interest
The authors declare no conflict of interest.
Acknowledgements
The Author would like to thank dr Adam 
Białas for his graphical assistance.
References:
1. Simonavicius E, McNeill A, Shahab L, et al. Heat-not-burn 
tobacco products: a  systematic literature review. Tob Con-
trol. 2018 [Epub ahead of print], doi: 10.1136/tobaccocon-
trol-2018-054419, indexed in Pubmed: 30181382.
2. Tabuchi T, Gallus S, Shinozaki T, et al. Heat-not-burn to-
bacco product use in Japan: its prevalence, predictors and 
perceived symptoms from exposure to secondhand heat-not
-burn tobacco aerosol. Tob Control. 2018; 27(e1): e25–e33, 
doi: 10.1136/tobaccocontrol-2017-053947, indexed in Pub-
med: 29248896.
3. Brose L, Simonavicius E, Cheeseman H. Awareness and use 
of ‚heat-not-burn‘ tobacco products in Great Britain. Tobacco 
Regulatory Science. 2018; 4(2): 44–50, doi: 10.18001/trs.4.2.4.
4. Chun LF, Moazed F, Calfee CS, et al. Pulmonary toxicity of 
e-cigarettes. Am J Physiol Lung Cell Mol Physiol. 2017; 313(2): 
L193–L206, doi: 10.1152/ajplung.00071.2017, indexed in Pub-
med: 28522559.
5. Dinakar C, O’Connor GT, Dinakar C, et al. The health effects of 
electronic cigarettes. N Engl J Med. 2016; 375(14): 1372–1381, 
doi: 10.1056/NEJMra1502466, indexed in Pubmed: 27705269.
6. Schick SF, Blount BC, Jacob P, et al. Biomarkers of exposure 
to new and emerging tobacco delivery products. Am J Physiol 
Lung Cell Mol Physiol. 2017; 313(3): L425–L452, doi: 10.1152/
ajplung.00343.2016, indexed in Pubmed: 28522563.
7. National Cancer Institute. NCI Dictionary of Cancer Terms. 
2017.
8. Gasparyan H, Mariner D, Wright C, et al. Accurate measu-
rement of main aerosol constituents from heated tobacco 
products (HTPs): Implications for a  fundamentally different 
aerosol. Regul Toxicol Pharmacol. 2018; 99: 131–141, doi: 
10.1016/j.yrtph.2018.09.016, indexed in Pubmed: 30244041.
9. Forster M, Fiebelkorn S, Yurteri C, et al. Assessment of no-
vel tobacco heating product THP1.0. Part 3: Comprehensive 
chemical characterisation of harmful and potentially harm-
ful aerosol emissions. Regul Toxicol Pharmacol. 2018; 93: 
14–33, doi: 10.1016/j.yrtph.2017.10.006, indexed in Pubmed: 
29080848.
10. Farsalinos KE, Yannovits N, Sarri T, et al. Nicotine delivery to 
the aerosol of a  heat-not-burn tobacco product: comparison 
with a  tobacco cigarette and e-cigarettes. Nicotine Tob Res. 
2018; 20(8): 1004–1009, doi: 10.1093/ntr/ntx138, indexed in 
Pubmed: 28637344.
11. Auer R, Concha-Lozano N, Jacot-Sadowski I, et al. JAMA In-
tern Med. 2017; 177: 1050–1052.
12. Bekki K, Inaba Y, Uchiyama S, et al. Comparison of chemicals 
in mainstream smoke in heat-not-burn tobacco and combu-
stion cigarettes. J UOEH. 2017; 39(3): 201–207, doi: 10.7888/
juoeh.39.201, indexed in Pubmed: 28904270.
13. Wilkinson GP, Burseg K, Stotesbury S, et al. Heated tobacco 
products create side-stream emissions: implications for regu-
lation. Journal of Environmental Analytical Chemistry. 2015; 
02(05), doi: 10.4172/2380-2391.1000163.
14. Protano C, Manigrasso M, Avino P, et al. Second-hand smoke 
exposure generated by new electronic devices (IQOS® and 
e-cigs) and traditional cigarettes: submicron particle behaviour 
in human respiratory system. Ann Ig. 2016; 28(2): 109–112, 
doi: 10.7416/ai.2016.2089, indexed in Pubmed: 27071321.
15. Ruprecht AA, Marco CDe, Saffari A, et al. Environmental 
pollution and emission factors of electronic cigarettes, he-
at-not-burn tobacco products, and conventional cigarettes. 
Aerosol Science and Technology. 2017; 51(6): 674–684, doi: 
10.1080/02786826.2017.1300231.
16. Protano C, Manigrasso M, Avino P, et al. Second-hand smoke 
generated by combustion and electronic smoking devices used 
in real scenarios: Ultrafine particle pollution and age-rela-
ted dose assessment. Environ Int. 2017; 107: 190–195, doi: 
10.1016/j.envint.2017.07.014, indexed in Pubmed: 28750224.
17. Pratte P, Cosandey S, Goujon Ginglinger C. Investigation of so-
lid particles in the mainstream aerosol of the Tobacco Heating 
System THS2.2 and mainstream smoke of a  3R4F reference 
cigarette. Hum Exp Toxicol. 2017; 36(11): 1115–1120, doi: 
10.1177/0960327116681653, indexed in Pubmed: 27932538.
18. Mitova MI, Campelos PB, Goujon-Ginglinger CG, et al. Com-
parison of the impact of the Tobacco Heating System 2.2 and 
a  cigarette on indoor air quality. Regul Toxicol Pharmacol. 
2016; 80: 91–101, doi: 10.1016/j.yrtph.2016.06.005, indexed 
in Pubmed: 27311683.
19. Forster M, McAughey J, Prasad K, et al. Assessment of tobacco 
heating product THP1.0. Part 4: Characterisation of indoor 
air quality and odour. Regul Toxicol Pharmacol. 2018; 93: 
34–51, doi: 10.1016/j.yrtph.2017.09.017, indexed in Pubmed: 
28989082.
20. Lopez AA, Hiler M, Maloney S, et al. Expanding clinical la-
boratory tobacco product evaluation methods to loose-leaf 
tobacco vaporizers. Drug Alcohol Depend. 2016; 169: 33–40, 
Advances in Respiratory Medicine 2019, vol. 87, no. 2, pages 123–134 
132 www.journals.viamedica.pl
doi: 10.1016/j.drugalcdep.2016.10.005, indexed in Pubmed: 
27768968.
21. Lüdicke F, Magnette J, Baker G, et al. A Japanese cross-sectio-
nal multicentre study of biomarkers associated with cardio-
vascular disease in smokers and non-smokers. Biomarkers. 
2015; 20(6-7): 411–421, doi: 10.3109/1354750X.2015.1096303, 
indexed in Pubmed: 26616146.
22. Lüdicke F, Picavet P, Baker G, et al. Reduced exposure to harm-
ful and potentially harmful smoke constituents with the tobac-
co heating system 2.1. Nicotine Tob Res. 2017; 19(2): 168–175, 
doi: 10.1093/ntr/ntw164, indexed in Pubmed: 27613951.
23. Lüdicke F, Haziza C, Weitkunat R, et al. Evaluation of bio-
markers of exposure in smokers switching to a carbon-heated 
tobacco product: a controlled, randomized, open-label 5-day 
exposure study. Nicotine Tob Res. 2016; 18(7): 1606–1613, doi: 
10.1093/ntr/ntw022, indexed in Pubmed: 26817490.
24. Titz B S, Boue S, Philips B, et al. Effects of cigarrete smoke, 
cessation, switching to two heat-not-burn tobacco products on 
lung lipid metabolism in C57BL/6 and apoe-/-mice-an inegra-
tive toxicology analysis. Toxicol Sci. 2016; 149(2): 441–457.
25. Phillips BW, Schlage WK, Titz B, et al. A 90-day OECD TG 413 
rat inhalation study with systems toxicology endpoints demon-
strates reduced exposure effects of the aerosol from the carbon 
heated tobacco product version 1.2 (CHTP1.2) compared with 
cigarette smoke. I. Inhalation exposure, clinical pathology and 
histopathology. Food Chem Toxicol. 2018; 116(Pt B): 388–413, 
doi: 10.1016/j.fct.2018.04.015, indexed in Pubmed: 29654848.
26. Haswell LE, Corke S, Verrastro I, et al. In vitro RNA-seq-based 
toxicogenomics assessment shows reduced biological effect of 
tobacco heating products when compared to cigarette smoke. 
Sci Rep. 2018; 8(1): 1145, doi: 10.1038/s41598-018-19627-0, 
indexed in Pubmed: 29402904.
27. Sewer A, Kogel U, Talikka M, et al. Evaluation of the tobacco 
heating system 2.2 (THS2.2). Part 5: microRNA expression 
from a 90-day rat inhalation study indicates that exposure to 
THS2.2 aerosol causes reduced effects on lung tissue compa-
red with cigarette smoke. Regul Toxicol Pharmacol. 2016; 81 
Suppl 2: S82–S92, doi: 10.1016/j.yrtph.2016.11.018, indexed 
in Pubmed: 27866933.
28. Zanetti F, Sewer A, Scotti E, et al. Assessment of the impact of 
aerosol from a potential modified risk tobacco product compa-
red with cigarette smoke on human organotypic oral epithe-
lial cultures under different exposure regimens. Food Chem 
Toxicol. 2018; 115: 148–169, doi: 10.1016/j.fct.2018.02.062, 
indexed in Pubmed: 29505817.
29. Haziza C, de La Bourdonnaye G, Merlet S, et al. Assessment 
of the reduction in levels of exposure to harmful and poten-
tially harmful constituents in Japanese subjects using a novel 
tobacco heating system compared with conventional cigarettes 
and smoking abstinence: A  randomized controlled study in 
confinement. Regul Toxicol Pharmacol. 2016; 81: 489–499, doi: 
10.1016/j.yrtph.2016.09.014, indexed in Pubmed: 27693654.
30. Haziza C, de La Bourdonnaye G, Skiada D, et al. Evaluation 
of the tobacco heating system 2.2. Part 8: 5-Day randomi-
zed reduced exposure clinical study in Poland. Regul Toxicol 
Pharmacol. 2016; 81 Suppl 2: S139–S150, doi: 10.1016/j.yr-
tph.2016.11.003, indexed in Pubmed: 27816672.
31. Kamada T, Yamashita Y, Tomioka H. Acute eosinophilic 
pneumonia following heat-not-burn cigarette smoking. Respi-
rology Case Reports. 2016; 4(6): e00190, doi: 10.1002/rcr2.190.
32. The Goverment Response to Science and Technology Comi-
tee’s Seventh Report of the Session 2017-19 on E-cigarettes. 
Dept Health&Social Care. 2018 Dec.
33. Belluz J, Philip Morris wanted to market a new tobacco device 
as safer than cigarretes. Vox 2018. www.vox.com/science-an-
d-health/2018.
34. Bialous SA, Glantz SA. Heated tobacco products: another to-
bacco industry global strategy to slow progress in tobacco con-
trol. Tob Control. 2018; 27(Suppl 1): s111–s117, doi: 10.1136/
tobaccocontrol-2018-054340, indexed in Pubmed: 30209207.
35. McMillen RC, Gottlieb MA, Shaefer RM, et al. Trends in 
electronic cigarette use among u.s. adults: use is increasing 
in both smokers and nonsmokers. Nicotine Tob Res. 2015; 
17(10): 1195–1202, doi: 10.1093/ntr/ntu213, indexed in Pub-
med: 25381306.
36. Ferkol TW, Farber HJ, La Grutta S, et al. Forum of International 
Respiratory Societies. Electronic cigarette use in youths: a po-
sition statement of the Forum of International Respiratory So-
cieties. Eur Respir J. 2018; 51(5), doi: 10.1183/13993003.00278-
2018, indexed in Pubmed: 29848575.
37. Jamal A, Gentzke A, Hu SS, et al. Tobacco use among middle 
and high school students — United States, 2011–2016. MMWR 
Morb Mortal Wkly Rep. 2017; 66(23): 597–603, doi: 10.15585/
mmwr.mm6623a1, indexed in Pubmed: 28617771.
38. Zarobkiewicz MK, Wawryk-Gawda E, Woźniakowski MM, et 
al. Tobacco smokers and electronic cigarettes users among Po-
lish universities students. Rocz Panstw Zakl Hig. 2016; 67(1): 
75–80, indexed in Pubmed: 26953585.
39. Kasza KA, Ambrose BK, Conway KP, et al. Tobacco-product 
use by adults and youths in the United States in 2013 and 
2014. N Engl J Med. 2017; 376(4): 342–353, doi: 10.1056/NEJ-
Msa1607538, indexed in Pubmed: 28121512.
40. Chaffee BW, Couch ET, Gansky SA. Trends in characteristics 
and multi-product use among adolescents who use electronic 
cigarettes, United States 2011-2015. PLoS One. 2017; 12(5): 
e0177073, doi: 10.1371/journal.pone.0177073, indexed in Pub-
med: 28475634.
41. Sung HY, Wang Y, Yao T, et al. Polytobacco use and nicotine 
dependence symptoms among US adults, 2012–2014. Nicotine 
Tob Res. 2018; 20(suppl_1): S88–S98, doi: 10.1093/ntr/nty050, 
indexed in Pubmed: 30125019.
42. Wilson FA, Wang Y. Recent Findings on the prevalence of 
e-cigarette use among adults in the U.S. Am J Prev Med. 2017; 
52(3): 385–390, doi: 10.1016/j.amepre.2016.10.029, indexed in 
Pubmed: 27988090.
43. Barrington-Trimis J, Leventhal A. Adolescents’ Use of “Pod 
Mod” E-Cigarettes — Urgent Concerns. N Engl J Med. 2018; 
379(12): 1099–1102, doi: 10.1056/nejmp1805758.
44. Breland A, Soule E, Lopez A, et al. Electronic cigarettes: what 
are they and what do they do? Ann N Y Acad Sci. 2017; 1394(1): 
5–30, doi: 10.1111/nyas.12977, indexed in Pubmed: 26774031.
45. Talih S, Balhas Z, Eissenberg T, et al. Effects of user puff to-
pography, device voltage, and liquid nicotine concentration 
on electronic cigarette nicotine yield: measurements and mo-
del predictions. Nicotine Tob Res. 2015; 17(2): 150–157, doi: 
10.1093/ntr/ntu174, indexed in Pubmed: 25187061.
46. Hess CA, Olmedo P, Navas-Acien A, et al. E-cigarettes as a so-
urce of toxic and potentially carcinogenic metals. Environ 
Res. 2017; 152: 221–225, doi: 10.1016/j.envres.2016.09.026, 
indexed in Pubmed: 27810679.
47. Talih S, Balhas Z, Salman R, et al. „Direct dripping“: a high
-temperature, high-formaldehyde emission electronic cigaret-
te use method. Nicotine Tob Res. 2016; 18(4): 453–459, doi: 
10.1093/ntr/ntv080, indexed in Pubmed: 25863521.
48. Hutzler C, Paschke M, Kruschinski S, et al. Chemical hazards 
present in liquids and vapors of electronic cigarettes. Arch 
Toxicol. 2014; 88(7): 1295–1308, doi: 10.1007/s00204-014-
1294-7, indexed in Pubmed: 24958024.
49. Carter T, Tucker D, Kilic A, et al. Life-threatening vesicular 
bronchial injury requiring veno-venous extracorporeal mem-
brane oxygenation rescue in an electronic nicotine delivery 
system user. Clin Pract Cases Emerg Med. 2017; 1(3): 212–
217, doi: 10.5811/cpcem.2017.3.33171, indexed in Pubmed: 
29849303.
50. Dimensionless group in fires and explosions. Fire Safety 
Journal. 1997; 29(2-3): 232–233, doi: 10.1016/s0379-
7112(97)90033-3.
51. Patterson SB, Beckett AR, Lintner A, et al. A  novel classi-
fication system for injuries after electronic cigarette explo-
sions. J Burn Care Res. 2017; 38(1): e95–e9e100, doi: 10.1097/
BCR.0000000000000471, indexed in Pubmed: 27893577.
52. Lisko JG, Tran H, Stanfill SB, et al. Chemical composition and 
evaluation of nicotine, tobacco alkaloids, ph, and selected 
flavors in e-cigarette cartridges and refill solutions. Nicotine 
Tob Res. 2015; 17(10): 1270–1278, doi: 10.1093/ntr/ntu279, 
indexed in Pubmed: 25636907.
53. Stepanov I, Fujioka N. Bringing attention to e-cigarette pH 
as an important element for research and regulation. Tob 
Control. 2015; 24(4): 413–414, doi: 10.1136/tobaccocon-
trol-2014-051540, indexed in Pubmed: 24827979.
Paweł Górski, E-cigarettes or heat-not-burn tobacco products
133www.journals.viamedica.pl
54. Abramovitz A, McQueen A, Martinez RE, et al. Electronic 
cigarettes: The nicotyrine hypothesis. Med Hypotheses. 2015; 
85(3): 305–310, doi: 10.1016/j.mehy.2015.06.002, indexed in 
Pubmed: 26100465.
55. Martinez RE, Dhawan S, Sumner W, et al. On-line chemical 
composition analysis of refillable electronic cigarette aerosol
-measurement of nicotine and nicotyrine. Nicotine Tob Res. 
2015; 17(10): 1263–1269, doi: 10.1093/ntr/ntu334, indexed in 
Pubmed: 25542921.
56. Mayer B. How much nicotine kills a human? Tracing back the 
generally accepted lethal dose to dubious self-experiments in 
the nineteenth century. Arch Toxicol. 2014; 88(1): 5–7, doi: 
10.1007/s00204-013-1127-0, indexed in Pubmed: 24091634.
57. Mowry JB, Spyker DA, Brooks DE, et al. 2015 Annual Re-
port of the American Association of Poison Control Cen-
ters‘ National Poison Data System (NPDS): 33rd Annual 
Report. Clin Toxicol (Phila). 2016; 54(10): 924–1109, doi: 
10.1080/15563650.2016.1245421, indexed in Pubmed: 
28004588.
58. Glasser AM, Collins L, Pearson JL, et al. Overview of electro-
nic nicotine delivery systems: a systematic review. Am J Prev 
Med. 2017; 52(2): e33–e66, doi: 10.1016/j.amepre.2016.10.036, 
indexed in Pubmed: 27914771.
59. Varlet V, Farsalinos K, Augsburger M, et al. Toxicity assess-
ment of refill liquids for electronic cigarettes. Int J Environ 
Res Public Health. 2015; 12(5): 4796–4815, doi: 10.3390/
ijerph120504796, indexed in Pubmed: 25941845.
60. Behar RZ, Davis B, Bahl V, et al. Identification of toxicants in 
cinnamon-flavored electronic cigarette refill fluids. Toxicol In 
Vitro. 2014; 28(2): 198–208, indexed in Pubmed: 24516877.
61. Behar RZ, Luo W, McWhirter KJ, et al. Analytical and toxico-
logical evaluation of flavor chemicals in electronic cigarette 
refill fluids. Sci Rep. 2018; 8(1): 8288, doi: 10.1038/s41598-
018-25575-6, indexed in Pubmed: 29844439.
62. Tierney PA, Karpinski CD, Brown JE, et al. Flavour chemi-
cals in electronic cigarette fluids. Tob Control. 2016; 25(e1): 
e10–e15, doi: 10.1136/tobaccocontrol-2014-052175, indexed 
in Pubmed: 25877377.
63. Flake GP, Morgan DL. Pathology of diacetyl and 2,3-pentanedio-
ne airway lesions in a rat model of obliterative bronchiolitis. 
Toxicology. 2017; 388: 40–47, doi: 10.1016/j.tox.2016.10.013, 
indexed in Pubmed: 27984136.
64. DeVito EE, Krishnan-Sarin S. E-cigarettes: impact of e-liquid 
components and device characteristics on nicotine exposure. 
Curr Neuropharmacol. 2018; 16(4): 438–459, doi: 10.2174/15
70159X15666171016164430, indexed in Pubmed: 29046158.
65. Farsalinos K, Spyrou A, Stefopoulos C, et al. Nicotine ab-
sorption from electronic cigarette use: comparison between 
experienced consumers (vapers) and naïve users (smokers). 
Scientific Reports. 2015; 5(1), doi: 10.1038/srep11269.
66. Volesky KD, Maki A, Scherf C, et al. The influence of three e-ci-
garette models on indoor fine and ultrafine particulate matter 
concentrations under real-world conditions. Environ Pollut. 
2018; 243(Pt B): 882–889, doi: 10.1016/j.envpol.2018.08.069, 
indexed in Pubmed: 30245450.
67. van Drooge BL, Marco E, Perez N, et al. Influence of electronic 
cigarette vaping on the composition of indoor organic pollu-
tants, particles, and exhaled breath of bystanders. Environ Sci 
Pollut Res Int. 2019; 26(5): 4654–4666, doi: 10.1007/s11356-
018-3975-x, indexed in Pubmed: 30560536.
68. Gerloff J, Sundar IK, Freter R, et al. Inflammatory respon-
se and barrier dysfunction by different e-cigarette flavoring 
chemicals identified by gas chromatography-mass spectrome-
try in e-liquids and e-vapors on human lung epithelial cells 
and fibroblasts. Appl In Vitro Toxicol. 2017; 3(1): 28–40, doi: 
10.1089/aivt.2016.0030, indexed in Pubmed: 28337465.
69. Scheffler S, Dieken H, Krischenowski O, et al. Evaluation of 
e-cigarette liquid vapor and mainstream cigarette smoke after 
direct exposure of primary human bronchial epithelial cells. 
Int J Environ Res Public Health. 2015; 12(4): 3915–3925, doi: 
10.3390/ijerph120403915, indexed in Pubmed: 25856554.
70. Aug A, Altraja S, Kilk K, et al. E-cigarette affects the meta-
bolome of primary normal human bronchial epithelial cel-
ls. PLoS One. 2015; 10(11): e0142053, doi: 10.1371/journal.
pone.0142053, indexed in Pubmed: 26536230.
71. Husari A, Shihadeh A, Talih S, et al. Acute exposure to elec-
tronic and combustible cigarette aerosols: effects in an animal 
model and in human alveolar cells. Nicotine & Tobacco Rese-
arch. 2015; 18(5): 613–619, doi: 10.1093/ntr/ntv169.
72. Boas Z, Gupta P, Moheimani RS, et al. Activation of the „Sple-
nocardiac Axis“ by electronic and tobacco cigarettes in other-
wise healthy young adults. Physiol Rep. 2017; 5(17), doi: 
10.14814/phy2.13393, indexed in Pubmed: 28899908.
73. Wu Q, Jiang Di, Minor M, et al. Electronic cigarette liquid 
increases inflammation and virus infection in primary human 
airway epithelial cells. PLoS One. 2014; 9(9): e108342, doi: 
10.1371/journal.pone.0108342, indexed in Pubmed: 25244293.
74. Kim KJ, Borok Z, Crandall ED. A  useful in vitro model for 
transport studies of alveolar epithelial barrier. Pharm Res. 
2001; 18(3): 253–255, indexed in Pubmed: 11442260.
75. Hwang JH, Lyes M, Sladewski K, et al. Electronic cigarette 
inhalation alters innate immunity and airway cytokines while 
increasing the virulence of colonizing bacteria. J Mol Med 
(Berl). 2016; 94(6): 667–679, doi: 10.1007/s00109-016-1378-3, 
indexed in Pubmed: 26804311.
76. Palpant NJ, Hofsteen P, Pabon L, et al. Cardiac development 
in zebrafish and human embryonic stem cells is inhibited by 
exposure to tobacco cigarettes and e-cigarettes. PLoS One. 
2015; 10(5): e0126259, doi: 10.1371/journal.pone.0126259, in-
dexed in Pubmed: 25978043.
77. Lerner CA, Sundar IK, Yao H, et al. Vapors produced by elec-
tronic cigarettes and e-juices with flavorings induce toxicity, 
oxidative stress, and inflammatory response in lung epithelial 
cells and in mouse lung. PLoS One. 2015; 10(2): e0116732, doi: 
10.1371/journal.pone.0116732, indexed in Pubmed: 25658421.
78. Schweitzer KS, Chen SX, Law S, et al. Endothelial disrupti-
ve proinflammatory effects of nicotine and e-cigarette vapor 
exposures. Am J Physiol Lung Cell Mol Physiol. 2015; 309(2): 
L175–L187, doi: 10.1152/ajplung.00411.2014, indexed in Pub-
med: 25979079.
79. Garcia-Arcos I, Geraghty P, Baumlin N, et al. Chronic electro-
nic cigarette exposure in mice induces features of COPD in 
a  nicotine-dependent manner. Thorax. 2016; 71(12): 1119–
1129, doi: 10.1136/thoraxjnl-2015-208039.
80. Sussan TE, Gajghate S, Thimmulappa RK, et al. Exposure 
to electronic cigarettes impairs pulmonary anti-bacterial and 
anti-viral defenses in a mouse model. PLoS One. 2015; 10(2): 
e0116861, doi: 10.1371/journal.pone.0116861, indexed in Pub-
med: 25651083.
81. McGrath-Morrow SA, Hayashi M, Aherrera A, et al. The effects 
of electronic cigarette emissions on systemic cotinine levels, 
weight and postnatal lung growth in neonatal mice. PLoS One. 
2015; 10(2): e0118344, doi: 10.1371/journal.pone.0118344, in-
dexed in Pubmed: 25706869.
82. Spindel E, McEvoy C. The role of nicotine in the effects of 
maternal smoking during pregnancy on lung development 
and childhood respiratory disease. implications for dangers of 
e-cigarettes. Am J Respir Crit Care Med. 2016; 193(5): 486–494, 
doi: 10.1164/rccm.201510-2013pp.
83. Wang MP, Ho SY, Leung LT, et al. Electronic cigarette use and 
respiratory symptoms in Chinese adolescents in Hong Kong. 
JAMA Pediatr. 2016; 170(1): 89–91, doi: 10.1001/jamapedia-
trics.2015.3024, indexed in Pubmed: 26551991.
84. Cho JHo, Paik SY. Association between electronic cigarette 
use and asthma among high school students in South Ko-
rea. PLoS One. 2016; 11(3): e0151022, doi: 10.1371/journal.
pone.0151022, indexed in Pubmed: 26942764.
85. Vardavas CI, Anagnostopoulos N, Kougias M, et al. Short-
term pulmonary effects of using an electronic cigarette: im-
pact on respiratory flow resistance, impedance, and exhaled 
nitric oxide. Chest. 2012; 141(6): 1400–1406, doi: 10.1378/
chest.11-2443, indexed in Pubmed: 22194587.
86. Scott A, Lugg ST, Aldridge K, et al. Pro-inflammatory effects of 
e-cigarette vapour condensate on human alveolar macropha-
ges. Thorax. 2018; 73(12): 1161–1169, doi: 10.1136/thoraxj-
nl-2018-211663, indexed in Pubmed: 30104262.
87. Yan XS, D‘Ruiz C. Effects of using electronic cigarettes on ni-
cotine delivery and cardiovascular function in comparison with 
regular cigarettes. Regul Toxicol Pharmacol. 2015; 71(1): 24–34, 
doi: 10.1016/j.yrtph.2014.11.004, indexed in Pubmed: 25460033.
Advances in Respiratory Medicine 2019, vol. 87, no. 2, pages 123–134 
134 www.journals.viamedica.pl
88. Szołtysek-Bołdys I, Sobczak A, Zielińska-Danch W, et al. Influ-
ence of inhaled nicotine source on arterial stiffness. Przegl Lek. 
2014; 71(11): 572–575, indexed in Pubmed: 25799846.
89. Benowitz NL, Fraiman JB. Cardiovascular effects of electronic 
cigarettes. Nat Rev Cardiol. 2017; 14(8): 447–456, doi: 10.1038/
nrcardio.2017.36, indexed in Pubmed: 28332500.
90. Pankow JF, Kim K, McWhirter KJ, et al. Benzene formation in 
electronic cigarettes. PLoS One. 2017; 12(3): e0173055, doi: 
10.1371/journal.pone.0173055, indexed in Pubmed: 28273096.
91. Shahab L, Goniewicz ML, Blount BC, et al. Nicotine, carcino-
gen, and toxin exposure in long-term e-cigarette and nicotine 
replacement therapy users: a cross-sectional study. Ann Intern 
Med. 2017; 166(6): 390–400, doi: 10.7326/M16-1107, indexed 
in Pubmed: 28166548.
92. Leigh NJ, Palumbo MN, Marino AM, et al. Tobacco-specific 
nitrosamines (TSNA) in heated tobacco product IQOS. Tob 
Control. 2018; 27(Suppl 1): s37–s38, doi: 10.1136/tobaccocon-
trol-2018-054318, indexed in Pubmed: 30242043.
93. Shaito A, Saliba J, Husari A, et al. Electronic cigarette smoke 
impairs normal mesenchymal stem cell differentiation. Sci 
Rep. 2017; 7(1): 14281, doi: 10.1038/s41598-017-14634-z, in-
dexed in Pubmed: 29079789.
94. Ramôa CP, Hiler MM, Spindle TR, et al. Electronic cigarette 
nicotine delivery can exceed that of combustible cigarettes: 
a  preliminary report. Tob Control. 2016; 25(e1): e6–e9, doi: 
10.1136/tobaccocontrol-2015-052447, indexed in Pubmed: 
26324250.
95. Sung HY, Wang Y, Yao T, et al. Polytobacco use and nicotine 
dependence symptoms among US adults, 2012–2014. Nicotine 
Tob Res. 2018; 20(suppl_1): S88–S98, doi: 10.1093/ntr/nty050, 
indexed in Pubmed: 30125019.
96. Chaffee BW, Couch ET, Gansky SA. Trends in characteristics 
and multi-product use among adolescents who use electronic 
cigarettes, United States 2011-2015. PLoS One. 2017; 12(5): 
e0177073, doi: 10.1371/journal.pone.0177073, indexed in Pub-
med: 28475634.
97. Pauly JR, Slotkin TA. Maternal tobacco smoking, nicoti-
ne replacement and neurobehavioural development. 
Acta Paediatr. 2008; 97(10): 1331–1337, doi: 10.1111/j.
1651-2227.2008.00852.x, indexed in Pubmed: 18554275.
98. Chatham-Stephens K, Law R, Taylor E, et al. Centers for Di-
sease Control and Prevention (CDC). Notes from the field: 
calls to poison centers for exposures to electronic cigarettes — 
United States, September 2010-February 2014. MMWR Morb 
Mortal Wkly Rep. 2014; 63(13): 292–293, indexed in Pubmed: 
24699766.
99. Vannier S, Ronziere T, Ferre JC, et al. Reversible cerebral va-
soconstriction syndrome triggered by an electronic cigarette: 
case report. Eur J Neurol. 2015; 22(5): e64–e65, doi: 10.1111/
ene.12657, indexed in Pubmed: 25846567.
100. Camus M, Gallois C, Gallois G, et al. Ulcerative colitis and 
electronic cigarette: what‘s the matter? Am J Gastroenterol. 
2014; 109(4): 608–609, doi: 10.1038/ajg.2013.439, indexed in 
Pubmed: 24698876.
101. McCauley L, Markin C, Hosmer D. An unexpected consequen-
ce of electronic cigarette use. Chest. 2012; 141(4): 1110–1113, 
doi: 10.1378/chest.11-1334, indexed in Pubmed: 22474155.
102. Hureaux J, Drouet M, Urban T. A  case report of subacute 
bronchial toxicity induced by an electronic cigarette. Thorax. 
2014; 69(6): 596–597, doi: 10.1136/thoraxjnl-2013-204767, 
indexed in Pubmed: 24436327.
103. Morjaria JB, Mondati E, Polosa R. E-cigarettes in patients with 
COPD: current perspectives. Int J Chron Obstruct Pulmon 
Dis. 2017; 12: 3203–3210, doi: 10.2147/COPD.S135323, in-
dexed in Pubmed: 29138548.
104. Bowler RP, Hansel NN, Jacobson S, et al. for COPDGene and 
SPIROMICS Investigators. Electronic Cigarette Use in US Adu-
lts at Risk for or with COPD: Analysis from Two Observational 
Cohorts. J Gen Intern Med. 2017; 32(12): 1315–1322, doi: 
10.1007/s11606-017-4150-7, indexed in Pubmed: 28884423.
105. Fairchild AL, Lee JuS, Bayer R, et al. E-Cigarettes and the 
harm-reduction continuum. N Engl J Med. 2018; 378(3): 
216–219, doi: 10.1056/NEJMp1711991, indexed in Pubmed: 
29342380.
106. McKeganey N, Dickson T. Why don‘t more smokers swi-
tch to using e-cigarettes: the views of confirmed smokers. 
Int J Environ Res Public Health. 2017; 14(6), doi: 10.3390/
ijerph14060647, indexed in Pubmed: 28621763.
107. Van Schayck OCP, Williams S, Barchilon V, et al. Treating 
tobacco dependence: guidance for primary care on life-saving 
interventions. Position statement of the IPCRG. NPJ Prim Care 
Respir Med. 2017; 27(1): 38, doi: 10.1038/s41533-017-0039-5, 
indexed in Pubmed: 28600490.
108. Konsumpcja nikotyny. Raport z badań ilościowych dla Biura do 
Spraw Substancji Chemicznych. CBOS Warszawa. 2018: 3–35.
109. Hajek P, Phillips-Waller A, Przulj D, et al. A randomized trial 
of e-cigarettes versus nicotine-replacement therapy. N Engl J 
Med. 2019; 380(7): 629–637, doi: 10.1056/NEJMoa1808779, 
indexed in Pubmed: 30699054.
110. Drazen JM, Morrissey S, Campion EW. The dangerous flavors 
of e-cigarettes. N Engl J Med. 2019; 380(7): 679–680, doi: 
10.1056/NEJMe1900484, indexed in Pubmed: 30699053.
